Development
Sanofi
SNY
$48.22
-$1.19-2.41%
NASDAQ
| 12/31/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 45.17B | 45.64B | |
| Total Other Revenue | -- | -- | 2.50B | 2.23B | |
| Total Revenue | -- | -- | 47.67B | 47.87B | |
| Cost of Revenue | -- | -- | 14.36B | 14.52B | |
| Gross Profit | -- | -- | 33.31B | 33.35B | |
| SG&A Expenses | -- | -- | 11.11B | 11.31B | |
| Depreciation & Amortization | -- | -- | 2.15B | 2.17B | |
| Other Operating Expenses | -- | -- | 1.76B | 1.92B | |
| Total Operating Expenses | -- | -- | 36.44B | 36.92B | |
| Operating Income | -- | -- | 11.23B | 10.95B | |
| Income Before Tax | -- | -- | 10.98B | 8.42B | |
| Income Tax Expenses | -- | -- | 2.08B | 1.46B | |
| Earnings from Continuing Operations | -- | -- | 8.90K | 6.96K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -118.17M | -71.37M | |
| Net Income | -- | -- | 8.78B | 6.89B | |
| EBIT | -- | -- | 11.23B | 10.95B | |
| EBITDA | -- | -- | 14.36B | 14.08B | |
| EPS Basic | -- | -- | 7.01 | 5.50 | |
| Normalized Basic EPS | -- | -- | 1.74 | 1.61 | |
| EPS Diluted | -- | -- | 7.01 | 5.50 | |
| Normalized Diluted EPS | -- | -- | 1.74 | 1.61 | |
| Average Basic Shares Outstanding | -- | -- | 5.01B | 5.01B | |
| Average Diluted Shares Outstanding | -- | -- | 5.01B | 5.01B | |
| Dividend Per Share | -- | -- | 3.64 | 3.81 | |
| Payout Ratio | -- | -- | -- | -- | |